Agoda and the Singapore Tourism Board Broaden their Cooperation to Increase Demand and Advance Technological Transformation in Tourism

On August 14, 2026, Kirin and GenerativeX have introduced an initiative developed to transform research and development by making use of generative AI. Kirin brings with it a great deal of experience in the fields of food,  pharmaceuticals, beverages, and health science, while GenerativeX specializes in helping businesses apply generative AI to business transformation. This partnership indicates the expanding trend amongst large companies of using AI frameworks for automating administrative tasks and represents a practical way of accelerating knowledge-intensive R&D efforts.

The more extensive significance is that AI-assisted research can minimize the time taken to go from information discovery to experimentation and commercialization. By combining its specialist knowledge with the capabilities of generative AI, the initiative could support  researchers in analyzing information more quickly, exploring ideas more efficiently, automating standard knowledge work, and improving partnership between R&D teams. For companies that have complicated R&D processes, this collaboration may result in the development of new models for human-AI cooperation and progress.

Impact on AI in Pharmaceutical Sector

The global AI in pharmaceutical market size was valued at USD 1.94 billion in 2025 and is predicted to increase from USD 2.51 billion in 2026 to approximately USD 18.99 billion by 2035, expanding at a CAGR of 25.62% from 2026 to 2035. 
According to Precedence Research, the pharmaceutical industry could gain significant benefits from AI-assisted research and development because research teams have to work with large amounts of experimental data, scientific literature, clinical information, and regulatory material. Generative AI could help researchers to combine their knowledge, identify possible areas for research, formulate suggestions, and speed up the process of documentation.

The pharmaceutical sector's focus on accuracy, validation, data privacy, intellectual property, and government oversight will remain necessary if the technology is to be employed responsibly.  Kirin’s involvement is particularly relevant as its business covers pharmaceutical infrastructure. As long as it is properly implemented, AI will reduce the time spent on repetitive analytical tasks and allow scientists to focus more on experimentation and decision-making.

Impact on the Generative AI in Supply Chain Sector

The global generative AI in supply chain market size is worth around USD 932.02 million in 2025 and is anticipated to reach around USD 34,243.44 million by 2035, growing at a CAGR of 43.39% over the forecast period from 2026 to 2035.
According to Precedence Research, Generative AI is capable of transforming product development in the supply chain of the food and beverage sector by helping researchers identify consumer trends, evaluate product ideas, look into new ingredients, and speed up the formulation process. These AI systems can examine a wide range of datasets and generate possible combinations or hypotheses that researchers can then test in the laboratory. 

Kirin has experience with beverages and health-related products, and the greatest benefit will result when AI supports scientific expertise rather than replacing sensory testing, laboratory validation, consumer research, and the human decision-making process. Additionally, faster experimentation could minimize development time and enable companies to respond more quickly to changes in customer demand.

Impact on the Generative AI in Manufacturing Sector

The global generative AI in manufacturing market size is expected to reach at USD 630.72 million in 2025 and is anticipated to reach around USD 13,893.51 million by 2034, expanding at a CAGR of 41% over the forecast period from 2025 to 2034.

According to Precedence Research, leading manufacturers are encouraging consumers to use generative AI to increase productivity in design, materials research, quality improvement, and process enhancement. The Kirin-GenerativeX initiative is an example of how large companies can integrate their specialized knowledge with specific AI capabilities to develop all technologies in-house. This would make the organization's accumulated knowledge more accessible and help lower duplication of effort across various departments.

The AI could help groups when searching their own knowledge bases, summarising technical documentation, comparing previous experiments, and generating new ideas based on existing research. For manufacturers, effective implementation will depend on a solid data foundation, appropriate employee training, secure AI infrastructure, and clear governance of the outputs.

Expert Opinion

From an expert point of view, the Kirin and GenerativeX initiative is strategically important because it clearly illustrates the area in which enterprise AI can create its greatest long-term value by helping experts in complex scientific settings. Generative AI can reduce the workload of these tasks and allow researchers to consider a larger number of alternatives within the same time frame. R&D teams generally spend a great deal of time searching for information, organizing their knowledge, reviewing documents, and preparing analyses before they can carry out meaningful experimentation. 
However, scientific R&D requires reproducibility, validation, evidence, and accountability, driving demand for AI that will be carefully examined by experts and confirmed in the laboratory. The real potential of the partnership will be demonstrated when Kirin can connect generative AI with its research knowledge, operational procedures, and actual innovation outcomes. Other companies should take this as an example of focused human-AI collaboration in place rather than just another example of generative AI being used.